We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Sanofi and Regeneron’s Dupixent for Eosinophilic Esophagitis
FDA Approves Sanofi and Regeneron’s Dupixent for Eosinophilic Esophagitis
The FDA approved Sanofi and Regeneron’s blockbuster monoclonal antibody, Dupixent (dupilumab), for patients 12 years and older with eosinophilic esophagitis, a rare chronic inflammatory disorder — making it the first FDA-approved treatment for the disease.